Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Phase 3
Recruiting
- Conditions
- Colorectal CancerVitamin CGLUT3
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT04516681
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Shanhai, Shanghai, China
A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients
Phase 2
- Conditions
- Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 51
- Registration Number
- NCT04516655
Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)
Phase 2
- Conditions
- Breast Cancer
- Interventions
- Drug: Eribulin,cisplatinDrug: Gemcitabine,cisplatin
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2020-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04517292
- Locations
- 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
Not Applicable
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Transcatheter Hepatic Arterial Chemoembolization (TACE)Procedure: Ablation
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-05-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04517227
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 97
- Registration Number
- NCT04517305
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Treatment After Palbociclib-containing Regimens
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2020-08-18
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT04517318
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: PD-1 antibody+ HDAC inhibitor
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 51
- Registration Number
- NCT04512534
- Locations
- 🇨🇳
Dongmei Ji, Shanghai, Shanghai, China
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
Phase 2
Completed
- Conditions
- Metastatic Gastric CancerLocally Advanced Gastric AdenocarcinomaGastric Cancer Adenocarcinoma Metastatic
- Interventions
- Procedure: R0 surgery
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT04510064
- Locations
- 🇨🇳
Fudan University, Shanghai Cancer Center, Shanghai, Shanghai, China
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Phase 3
Not yet recruiting
- Conditions
- Liver MetastasesColorectal CancerCetuximab
- Interventions
- Drug: Chemotherapy
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04509635
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
Phase 2
- Conditions
- Treatment Efficacy
- Interventions
- Drug: HX008，NiraparibDrug: HX008，Niraparib，TrastuzumabDrug: HX008，Niraparib，Pyrrolitinib
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 37
- Registration Number
- NCT04508803
- Locations
- 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath